0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover97.63%IV-15.65%PremiumSep 20, 2024Expiry Date2.32Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8010Delta0.0789Gamma5.29Leverage Ratio-0.0240Theta0.0054Rho4.24Eff Leverage0.0101Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet